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Breast cancer risk is increased in the years following
false-positive breast cancer screening
Mathijs C. Goossensa,c, Isabel De Brabanderb, Jacques De Grevea,
Evelien Vaesb, Chantal Van Ongevald, Koen Van Herckc,e and Eliane Kellenc,d
A small number of studies have investigated breast cancer
(BC) risk among women with a history of false-positive
recall (FPR) in BC screening, but none of them has used
time-to-event analysis while at the same time quantifying
the effect of false-negative diagnostic assessment (FNDA).
FNDA occurs when screening detects BC, but this BC is
missed on diagnostic assessment (DA). As a result of
FNDA, screenings that detected cancer are incorrectly
classified as FPR. Our study linked data recorded in the
Flemish BC screening program (women aged 50–69 years)
to data from the national cancer registry. We used Cox
proportional hazards models on a retrospective cohort of
298 738 women to assess the association between FPR and
subsequent BC, while adjusting for potential confounders.
The mean follow-up was 6.9 years. Compared with women
without recall, women with a history of FPR were at an
increased risk of developing BC [hazard ratio= 2.10 (95%
confidence interval: 1.92–2.31)]. However, 22% of BC after
FPR was due to FNDA. The hazard ratio dropped to 1.69
(95% confidence interval: 1.52–1.87) when FNDA was
excluded. Women with FPR have a subsequently increased
BC risk compared with women without recall. The risk is
higher for women who have a FPR BI-RADS 4 or 5
compared with FPR BI-RADS 3. There is room for
improvement of diagnostic assessment: 41% of the excess
risk is explained by FNDA after baseline
screening. European Journal of Cancer Prevention
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Introduction
Widespread implementation of mammographic screening
for breast cancer (BC) has the potential of decreasing BC
mortality but also involves a risk of adverse effects such
as overdiagnosis and false-positive recall (FPR) (Marmot
et al., 2013).
FPR means a woman was recalled due to suspicious
findings on the screening mammogram, but no evidence
of BC was found at diagnostic assessment (DA).
However, DA is not infallible: when cancers that were
seen at screening are missed at DA, this is called false-
negative diagnostic assessment (FNDA). When FNDA
occurs, screenings that detected BC are incorrectly clas-
sified as FPR. In other words, recall can be either true-
positive (screen-detected cancer) or false-positive (no
screen-detected cancer), but occasionally a FPR turns out
to be a true-positive recall that was misclassified as false-
positive because DA failed to find the cancer that was
seen at screening (Duijm et al., 2004; von Euler-Chelpin
et al., 2014).
In Europe, women aged 50–69 years have a cumulative
risk of between 8 and 32% of having at least one FPR
over the course of 10 screening rounds (Castells et al.,
2006; Hofvind et al., 2012). This variation can be
explained by differences in screening organization, pro-
tocol characteristics, recall rates, and a woman’s own risk
profile (Christiansen et al., 2000; Castells et al., 2006).
The Recall rate is the number of women recalled for
assessment as a proportion of all women who had a
screening examination. According to the European
guidelines, recall rates should be below 7% in first round
screenings (preferably below 5%) and below 5% in sub-
sequent round screenings (preferably below 3%). FPR
has several disadvantages, which include patients
experiencing anxiety while waiting for the result,
decreasing reattendance rates in the next screening
round, increasing financial burden on the healthcare
system, and increasing workload for healthcare staff
(Bangsboll-Andersen et al., 2008; Alamo-Junquera et al.,
2011; Maxwell et al., 2013; Goossens et al., 2014). Women
who have had an FPR are also at an increased risk for BC
compared with women who were not recalled. The
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relative risk for BC after FPR has been estimated to be
between 1.67 [95% confidence interval (CI): 1.45–1.88]
and 2.69 (95% CI: 2.28–3.16) and may be highest for
women who underwent fine-needle aspiration cytology
(FNAC) or core-needle biopsy (CNB) during assessment
(von Euler-Chelpin et al., 2012; Castells et al., 2013;
Henderson et al., 2015).
However, not all of these studies correct for FNDA and it
is unclear as to what proportion of the risk is attributable
to FNDA. Deciding whether a recall led to a screen-
detected cancer (SDC) or whether it was an FPR requires
knowledge of the conclusion of DA; this is why the
Flemish BC screening program systematically contacts
the woman’s physician after each recall to request the DA
conclusion. For screenings in 2005 and 2006, this pro-
vided a clear conclusion (SDC or no cancer) for about
77% of recalls; the remaining 23% either consists of
nonresponse or of indecisive conclusions (unknown
results, refusal to perform DA, etc.). This method alone is
not sufficient for a study such as this one as it does not
provide information on the BC status of women who
were not recalled, or for whom the DA conclusion is not
available, and it does not follow-up women in the years
after screening. Another way to decide whether a recall
led to an SDC is to use cancer registry data. The
advantage of this option is that these data are routinely
available and the degree of completeness and accuracy
can be estimated. They are also available for women
without recall, and allow women to be followed through
the years after screening. However, although cancer
registry data typically provide a date of diagnosis, they do
not usually include information from DA, such as whe-
ther it is an SDC. A frequently used solution is to decide
on a cutoff period for the time between recall and the
date of diagnosis within which a BC is assumed to have
been found at the DA following screening and is there-
fore an SDC. Some studies that investigated the risk for
BC after FPR have put this cutoff at 12 months after
recall (Peeters et al., 1988; Henderson et al., 2015),
whereas some studies do not explain in detail how they
determine SDC status (von Euler-Chelpin et al., 2012;
Castells et al., 2013). Although this is a pragmatic
approach, using a 12-month cutoff means that some BC
classified as SDC were in reality not found at the DA
after screening.
The type of statistical analysis of the studies investigating
the risk for BC after FPR is also up for debate: the out-
come variable in BC studies can either be seen as
dichotomous (cancer/no cancer), or as the time elapsed
until BC. In the first case, logistic or Poisson regression is
a good choice, whereas in the second case a time-to-event
analysis would be warranted. Even though both analysis
options are defendable, studies with a long follow-up
period will have patients who are censored before the
end of the study. With logistic regression these patients
would have to be excluded from the study or be assumed
not to have had the event, but time-to-event analysis is
able to deal with censored data. In our view, this makes
time-to-event analysis the preferred method of analysis
(Hosmer and Lemeshow, 2000). To our knowledge, only
one study has investigated long-term BC risk after FPR
using time-to-event analysis (such as Cox proportional
hazards models), but this study did not investigate the
role of FNDA (Henderson et al., 2015).
Further research on FPR as a risk factor for BC is
important because an adapted follow-up regimen might
be indicated if the risk for BC is considerably increased
for these women. In the current study we apply time-to-
event analysis on a retrospective cohort of screened
women to estimate their BC risk, while taking FNDA
into account.
Patients and methods
Setting
The Belgian region of Flanders has about 1.4 million
female inhabitants between 50 and 69 years of age and has
a BC screening program compliant with relevant European
guidelines (Perry et al., 2008). Within the BC screening
program, every 2 years all eligible women in the age group
50–69 years receive an invitation letter with a set
appointment for a BC screening mammogram. Women at
an increased risk for breast cancer are not excluded from
the mailing list, but are advised to discuss with their
physician whether the organized MBCS program is sui-
table for them, or whether they would benefit more from
other types of prevention. Flanders also has opportunistic
screening, which is by prescription only. Opportunistic
screening, unlike the BC screening program, does not
include organized quality control (e.g. double reading), its
data are not stored in one central database, and it is not
free of charge. Women with BC found through opportu-
nistic screening have been excluded from the BC
screening program mailing list since 2016. The percentage
of women screened in Flanders during the period
2006–2007 was 21% in opportunistic screening and 44%
through the BC screening program, giving a total coverage
of 65% (Intermutualistisch Agentschap, 2010).
Screening in the BC screening program always consists of
a two-view mammogram (medio-lateral-oblique and cra-
nio-caudal) of each breast, without ultrasound or clinical
breast examination. All examinations are read indepen-
dently by two certified screening radiologists, both of
whom use a scoring system to describe whether they
recommend recall. This system resembles the Breast
Imaging Reporting and Data System (BI-RADS):
0= screening mammogram is of insufficient quality to
make a conclusion, 1=no abnormality, 2= benign lesion,
3= probably benign lesion, 4=probably malignant
lesion, and 5=highly suspicious for malignancy. If the
two readers have discrepant assessments, a third reader is
consulted. Score 0 will lead to the women being recalled
for a new mammogram without any conclusion on the
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presence of cancer. Recall for assessment will always be
recommended for scores 3, 4 and 5, whereas no recall will
be requested for scores 1 and 2.
Irrespective of whether recall score 3, 4 or 5 is used,
readers can advise DA either to take place as soon as
possible or to be performed 6 or 12 months after
screening without any immediate assessment (short-
interval follow-up). For recall score 3, immediate addi-
tional imaging was recommended for 97.3% of recalls;
the remaining 2.7% were recommended short-interval
follow-up. For recall scores 4 or 5 the corresponding
percentages were 99.4 and 0.6%. A recommendation for
the DA type is sent to the woman’s physician along with
the screening result and can include noninvasive proce-
dures (MRI, ultrasound, and additional mammography)
and/or invasive (fine-needle aspiration cytology, core-
needle biopsy and open biopsy). About 96% of women
receive their results within 3 weeks of screening and
more than 90% of DA is performed within 1 month after
recall (Martens et al., 2015).
Besides screening interpretation, readers also estimate
breast density, classified according to the percentage of
fibroglandular tissue (A≤ 25%, B= 26 – 50%, C= 51–75%,
D> 75%).
Ethics statement
When registering for mammographic screening, all women
are asked to provide written consent for their data to be
used in research related to the quality of the screening
program. The Sectoral Committee of Social Security and
Health (the national privacy commission) approved the use
of a unique patient identifier to crosslink screening data to
oncological data from the national population-based cancer
registry (Belgian Cancer Registry, BCR) for women who
signed such informed consent.
Study population
Supplementary Fig. S1 (Supplemental digital content 1,
http://links.lww.com/EJCP/A122) shows the study flow
diagram. We built a retrospective cohort of all women
who participated in the Flemish BC screening program
between January 2005 and December 2006. Exclusion
criteria were as follows: lack of a signed informed consent
form and BC diagnosis preceding the baseline screening.
The remaining cohort (n= 292 731) was then split into
three groups: no recall; recall score 3; and recall score 4 or
5. Women with SDCs or women who were recalled but
did not go for diagnostic assessment within 12 months of
recall were excluded from groups of recalled women; this
led to three groups in the study [Supplementary Fig. S1
(Supplemental digital content 1, http://links.lww.com/
EJCP/A122)]:
(1) group without recall,
(2) FPR 3 group (FPR after a recall for probably benign
lesion),
(3) FPR 4/5 group (FPR after a recall for probably
malignant or highly suspicious lesion).
Study follow-up
The follow-up period started at baseline screening (T0)
for all participants in the study. At the time of this study,
BCR data on cancer incidence were complete until the
end of the year 2012; the follow-up of this study therefore
ends on 31 December 2012. Loss to follow-up was
defined as emigration out of Belgium before the end of
follow-up. Individual data on emigration and vital status
were obtained through linkage with the Crossroads Bank
for Social Security (CBSS).
Primary outcome
The primary outcome of this study was time to incident
BC. BC was defined as invasive carcinoma or ductal in-
situ carcinoma of the breast (C50 and D05, respectively,
of ICD-O, third edition, version 10).
Definition of false-positive recall and screen-detected
cancer
Women with FPR were found by removing all SDCs (the
true positives) from the group of recalled women. This
means that defining SDCs is in fact the first step to
defining FPR. In our study, BCs were classified as SDCs
if they were diagnosed within 3 months of the date of DA
(which is available through the BCR). This method uses
cancer registry data and includes a risk of under-
estimating SDC; in the discussion we will therefore
compare the results of this method with the results based
on the conclusions from DA obtained from the women’s
physicians.
Definition of false-negative diagnostic assessment
Location data are routinely registered in the screening
database and the BCR, and include up to 10 different
segments in each breast. Table 1 shows how location data
together with the timing of diagnosis were used to clas-
sify BCs after FPR as either FNDA or new cancers (BC
unrelated to the T0 recall). The cancers in the group
without recall at T0 were not classified.
Statistical analysis
When appropriate, sample characteristics were compared
between the three groups using the χ2-test, Fisher’s exact
test, or one-way analysis of variance. Incidence rates were
calculated as the number of BC per 100 000 person-years.
We calculated cumulative BC incidence estimates by
constructing time-to-event curves using Kaplan–Meier
estimates for each group (no recall, FPR score 3, and FPR
score 4/5 recall) and used the log-rank test to calculate
corresponding P-values.
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Cox proportional hazards models were used to calculate
hazard ratios (HRs). Confounding variables were candi-
dates for purposeful selection if they had P-values of 0.20
or less in univariate Cox proportional hazards models; age
(years), screening round (initial vs. successive) and breast
density (categories visible in Table 2) were tested.
Forward model selection was carried out using the like-
lihood ratio test, with significance set at P of 0.01 or less.
Multivariate HRs were thus adjusted for confounding
variables. A sensitivity analysis was performed that pre-
sumed all unclassifiable BC were FNDA.
The risk that a BC that was seen at screening would be
missed at assessment was estimated as follows:
Risk ¼ number of FNDA
number of FNDAþ number of SDC
The FNDA rate was calculated as the percentage of
FNDA among all women recalled to assessment.
The χ2-test was used to compare differences in tumor
behavior, size, grade, and nodal status between the BC
that were detected at DA (SDC), and those that were
missed at DA (FNDA).
Analyses and data storage were conducted using the
software package Stata, version 13 (StataCorp., College
Station, Texas, USA); all statistical tests were two sided.
Results
Sample size and follow-up
After exclusions, the group without recall included
281 247 women (1 927 608 person-years), the FPR 3
group included 10 597 women (72 145 person-years), and
the FPR 4/5 group included 840 women (5701 person-
years) [Supplementary Fig. S1 (Supplemental digital
content 1, http://links.lww.com/EJCP/A122), Table 2]. The
mean follow-up duration in years (± SD) was 6.9 (± 0.8),
6.8 (± 0.8), and 6.8 (± 1.0) in the no recall group, FPR 3
group, and FPR 4/5 group, respectively. Baseline char-
acteristics of these groups are presented in Table 2; the
Table 1 Using location data and the timing of diagnosis to classify breast cancers after false-positive recall as either false-negative
diagnostic assessment or new cancers
Was BC found in the segment for which recall was recommended at T0?
No Yes
When was BC diagnosed?
Before the first screening that followed T0 recall New BC FNDA
At the first screening that followed T0 recall New BC FNDA
At the second or later screening after T0 recall, with the intermediate screenings being
positive
New BC FNDA
At the second or later screening after T0 recall, with the intermediate screenings being
negative
New BC New BC
BC, breast cancer; FNDA, false-negative diagnostic assessment at T0.
Table 2 Baseline characteristics and follow-up of study participants
No recall FPR score 3 FPR score 4/5 P-valuea
n 281 247 10 597 840
Mean age in years (SD) 58.2 (5.7) 57.3 (5.9) 58.1 (5.8) <0.001
Screening round <0.001
Initial 95 953 (34.1) 5452 (51.4) 395 (47.0)
Successive 185 294 (65.9) 5145 (48.6) 445 (53.0)
Breast density categoryb <0.001
A (≤25%) 45 268 (16.1) 946 (9.0) 79 (9.4)
B (26–50%) 150 372 (53.5) 5829 (55.2) 412 (49.3)
C (51–75%) 70 082 (25.0) 3276 (31.0) 302 (36.1)
D (>75%) 15 186 (5.4) 508 (4.8) 43 (5.1)
Missing 339 (–) 38 (–) 4 (–)
Mean follow-up in years (SD) 6.9 (0.8) 6.8 (0.8) 6.8 (1.0)
Person-years 1 927 608 72 145 5701
Breast cancers 5708 384 59
Incidence rate (95% CI)c 296.1 (288.5–303.9) 532.3 (480.5–588.1) 1034.9 (788.7–1333.0)
Classification
New cancer 5,708 (100.0) 261 (78.1) 33 (73.3)
FNDA 0 (0.0) 73 (21.9) 12 (26.7)
Unclassifiable 0 (–) 50 (–) 14 (–)
Flanders, Belgium, 2005–2012.
Data are n (%) unless noted differently.
FNDA, false-negative diagnostic assessment at T0; FPR, false-positive recall at T0.
aP-value based on χ2-test or one-way analysis of variance (for age).
bCategories based on percentage fibroglandular tissue.
cPer 100 000 person-years.
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mean age in years (± SD) was 58.2 (± 5.7), 57.3 (± 5.9), and
58.1 (± 5.8) in the no recall group, the FPR 3 group, and
the FPR 4/5 group, respectively. Women in an initial
round were more likely to have a false-positive recall, as
were women with higher mammographic breast density.
Primary outcome and categorization of breast cancer
BC incidence is presented in Table 2; a total of 6151 BC
were found, of which 443 (7.2%) occurred in the FPR
groups. Of those 443 BC, the classification status could
not be determined for 64 BC (14.5%). Of the 379
remaining BC, 294 (77.6%) were new, whereas 85
(22.4%) were FNDA.
Risk estimates
Figure 1 presents time-to-event curves for the primary
endpoint (BC incidence). Dotted lines reflect the curves
that take all BC into account, whereas the solid lines
exclude FNDA.
When all BC were included, the 5-year cumulative BC
incidence was significantly different (P< 0.001) among
the groups: 1.4% in the no recall group, 2.7% in the FPR
3 group, and 5.7% in the FPR 4/5 group. After excluding
FNDA, the differences remained significant, but 5-year
cumulative BC incidence in the FPR groups decreased to
2.1% (FPR 3) and 4.3% (FPR 4/5).
The final multivariate Cox model included the following
variables as confounders: age, screening round, and
breast density. Figure 2 shows the HRs; the no-recall
group always serves as a reference. Overall, the HR of
any type of FPR was 1.90 (95% CI: 1.72–2.09) when all
BC were included and decreased to 1.53 (95% CI:
1.38–1.70) after excluding FNDA. This decrease from
1.90 to 1.53 represents a 41% drop.
The FPR 4/5 group had higher HRs compared with the
FPR 3 group. Before excluding FNDA, HRs were 3.43
(95% CI: 2.65–4.43) and 1.77 (95% CI: 1.60–1.97),
respectively, which decreased to 2.73 (95% CI:
2.05–3.64) and 1.44 (95% CI: 1.28–1.61). In sensitivity
analysis, which excluded the unclassifiable BC as well,
the risk estimates were 1.92 (95% CI: 1.36–2.70) and 1.21
(95% CI: 1.06–1.37), respectively.
Cancers missed at diagnostic assessment
There was a 4.3% risk that a BC that was seen at
screening would subsequently be missed at DA. This
corresponds to an FNDA rate of 0.64% among women
recalled to assessment. There were no significant dif-
ferences in tumor characteristics (Table 3).
Discussion
To our knowledge, this is the second study that uses
time-to-event analysis to investigate BC risk after FPR,
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but the first that also quantifies the effect of FNDA.
Women with a history of FPR were at an increased risk of
developing BC compared with women who were not
recalled, but 41% of the risk increase was due to FNDA.
The type of recall was clearly correlated with the risk.
After excluding FNDA, an FPR with BI-RADS 4 or 5
had an HR of 2.73 (95% CI: 2.05–3.64), whereas the risk
after an FPR with BI-RADS 3 had a lower HR (HR 1.44;
95% CI: 1.28–1.61).
When we included all BC, our risk estimates (HR 1.90;
95% CI: 1.72–2.09) were comparable to the findings in
other countries: a Spanish study (Castells et al., 2013)
found odds ratios between 1.81 and 2.69, a Danish study
(von Euler-Chelpin et al., 2012) found a relative risk (RR)
of 1.67, and two studies performed in the USA (Barlow
et al., 2006; Henderson et al., 2015) found HR of up to
1.76 and RR of 1.69. When we excluded FNDA, our risk
estimates (HR 1.53; 95% CI: 1.38–1.70) were slightly
higher than those in the only other study (odds ratio 1.27)
that we found that also excluded FNDA cancers (von
Euler-Chelpin et al., 2014). When FNDA was not
excluded, this particular study also had the lowest risk
estimates of the previous studies. Their percentage of
FNDA among all cancers after FPR was similar (24.4 vs.
our 22.4%).
This additional BC risk should be addressed in three
ways: decreasing FNDA, informing patients, and con-
sidering increased surveillance of women with FPR. As
regards decreasing FNDA, clearly there is room for
improvement of diagnostic assessment. Of all cancers
that were seen at screening, 4.3% were subsequently
missed at DA. Avoiding such FNDA would increase the
BC detection rate from 6.3 to 6.6‰. A previous study
found that the majority of FNDA are due to erroneously
interpreting suspicious lesions as benign, disregarding a
radiologist’s advice to perform a biopsy, and false-
negative biopsy results (Burrell et al., 2001; Duijm et al.,
2004; Ciatto et al., 2007). Reasons for not performing
biopsy include a surgeon’s refusal to perform biopsy even
after a radiologist’s explicit advice to do so (Duijm et al.,
2004). It has also been suggested that DA should be
performed in special breast care units (Purushotham et al.,
2001; Haward et al., 2003). Periodically evaluating the
quality of DA together with regular feedback might be
the best way forward. As regards informing patients,
increasing emphasis is placed on providing absolute risk
indicators such as 5-year cumulative BC incidence. Such
absolute risk indicators are necessary for informed deci-
sion making and provide much more information than
the RR (Mathieu et al., 2007; Akl et al., 2011). In absolute
terms, the increase in risk corresponded to a 5-year
Fig. 2
FPR, all types (n= 11 484)
Adjusted hazard ratios (95% CI)† P-value†
All BC 1.90 (1.72−2.09) <0.001
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<0.001
0.5 1.0 2.0 4.0 8.0
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1.77 (1.60−1.97)
1.44 (1.28−1.61)
3.43 (2.65−4.43)
2.73 (2.05−3.64)
All BC
All BC
All BC excluding FNDA
FPR score 3 (n= 10 597)
FPR score 4/5 (n= 840)
All BC excluding FNDA
All BC excluding FNDA
Adjusted hazard ratio (HR) from Cox proportional hazards models for breast cancer screening result. Flanders, Belgium, 2005–2012. †HR with
adjustment for age, breast density, and screening round. Reference category was always the no-recall group (not visible). BC, breast cancer;
CI, confidence interval; FNDA, false-negative diagnostic assessment at T0; FPR, false-positive recall at T0.
Table 3 Tumor characteristics of breast cancers found as screen-
detected cancer or false-negative diagnostic assessment
SDC FNDA P-valuea
Total number of breast cancers 1873 (100.0) 85 (100.0)
Behavior 0.206
DCIS 338 (18.1) 20 (23.5)
Invasive 1529 (81.9) 65 (76.5)
Missing 6 (–) 0 (–)
Tumor sizeb 0.716
≤10 mm 455 (33.3) 22 (35.5)
>10mm 913 (66.7) 40 (64.5)
Missing 161 (–) 3 (–)
Gradeb 0.788
Low 284 (20.3) 11 (18.0)
Intermediate 686 (49.1) 29 (47.5)
High 426 (30.5) 21 (34.4)
Missing 133 (–) 4 (–)
Nodal statusb 0.770
Negative 999 (75.0) 45 (73.3)
Positive 364 (25.0) 15 (26.7)
Missing 166 (–) 5 (–)
Flanders, Belgium, 2005–2012.
Data are n (%).
DCIS, ductal carcinoma in situ; FNDA, false-negative diagnostic assessment at
T0; SDC, screen-detected cancer.
aP-value based on χ2-test.
bFor invasive cancers only.
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cumulative BC incidence of 5.7% after a BI-RADS 4 or 5
FPR, versus 1.4% for women who were not recalled. As
regards yearly radiological evaluation, this would require
further studies to prove effectiveness.
Our study has several strengths and limitations. First, our
conclusions rely on the completeness of BCR and CBSS
data. Oncological care programs in hospitals and pathol-
ogy laboratories are required by law to supply the BCR
with their data. For the Flemish region, cancer incidence
data were available from 1999 until the end of 2012. The
completeness of the BCR as regards BC was evaluated
using the independent database method and was esti-
mated to be 99.7% until the end of 2012 (Henau et al.,
2015). One of the main sources of data for the CBSS is
the National Registry of the Ministry of the Interior,
which contains information on all people who were at
some point registered with a municipality in Belgium.
Cross-linking of the National Registry with the CBSS’s
other sources is performed to obtain data on people who
were not registered in the National Registry. The CBSS
is thought to have a degree of completeness in excess of
99%.
Second, we defined SDCs as BCs that are diagnosed
within 3 months of DA. This method (hereafter referred
as the 3-month algorithm) is more restrictive than the
definition of SDC that some authors use (all BC found
within 12 months of a positive screening are SDC)
(Christiansen et al., 2000; Henderson et al., 2015), but in
other manuscripts it is often unclear how SDC are
defined. The 3-month algorithm has the advantage of not
overestimating the number of SDC, but it is possible that
we underestimated the number of SDC. The result of
this would be that a woman with an SDC is seen as a
woman with FPR followed by BC. To check this, we
compared the DA conclusion sent by physicians with the
results of the 3-month algorithm. Of the 13 334 women
who were recalled (who had given informed consent and
did not have BC before screening, see flow chart), we
excluded 3112 women (23.4%) for whom we did not have
a DA conclusion sent by physicians (BC, no BC). When
the DA conclusion sent by physicians was compared with
the conclusion of the 3-month algorithm for the remain-
ing 10 198 women, we found that 1550 women had an
SDC according to both methods, but the DA conclusion
sent by physicians found an additional 16 SDC. Three of
these (18.8%) could not be SDC as they were not found
in the location of the lesion seen at screening. The
remaining 13 (81.2%) had a median time between DA
and diagnosis of 6 months. These 13 represent 0.8% of all
SDC. Although underestimation exists, we conclude that
it is limited.
Third, to classify BC after FPR as either FNDA or new
cancer, we used an algorithm that mainly used location
data, which are routinely collected in both the BCR and
the screening program. Compared with radiological
review of all files, such an algorithm has several important
advantages, including avoiding radiologist subjectivity, a
much lower workload, and more complete data (Blanch
et al., 2014). We cannot exclude that some cases were
categorized as FNDA, although these BC were in reality
unrelated to the lesion seen at screening, meaning we
would overestimate the FNDA rate. However, our
FNDA rate of 0.64% among women recalled to assess-
ment is situated between the 0.50% estimate found by
Ciatto et al. (2007), the 0.56% found by Burrell et al.
(2001), and the 1.5% found by von Euler-Chelpin et al.
(2014).
Moreover, the proportion of all BC that is seen at
screening but missed at DA (4.3%) is very similar to the
estimate found by Ciatto et al. (2007). We conclude that,
although some of the cancers classified as FNDA may
have in fact been new cancers, this is likely to be limited.
Fourth, noninformative censoring is an important
assumption in time-to-event analysis. However, when a
woman dies (due to any cause) she will no longer be at
risk for the primary outcome. The events of dying and of
developing BC are therefore not independent. As the
naïve Kaplan–Meier estimator assumes independence of
all events and thus censors the deaths, it can lead to an
overestimated risk of disease by failing to account for the
competing risk of death. This is mostly a problem when
the competing risk of death is high due to, for instance,
increased age or comorbidities. Even though a standard
Cox proportional hazards regression is not adequate in a
competing risk setting it can still be used to assess HRs of
FPR (Haesook, 2007; Putter et al., 2007). The resulting
HR will be slightly biased if the competing event of
death due to any cause is very rare. The advantages of
using the Cox model in this setting are that it makes
multivariate modeling possible and its HR are relatively
easy to interpret. To evaluate whether our results could
be overestimated we compared application of the
Kaplan–Meier method and the cumulative incidence
competing risk method (which calculates cumulative
incidence accounting for the presence of competing
risks) for each group in the study (Verduijn et al., 2011).
The Kaplan–Meier method overestimated the 5-year risk
for BC by less than 0.06% in each group. We conclude
that this bias is very limited and does not influence our
results.
Conclusion
Women with FPR are at an increased risk of developing
BC in the years after screening, and the type of recall is
clearly correlated with the magnitude of the risk. A part
of the risk is explained by FNDA, but the risk remains
significant after excluding FNDA.
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